European Journal of General Medicine
Medical Investigations Society
Vol. 3, No. 3, 2006, pp. 116-120
Bioline Code: gm06024
Full paper language: English
Document type: Research Article
Document available free of charge
European Journal of General Medicine, Vol. 3, No. 3, 2006, pp. 116-120
© Copyright 2006 - Medical Investigations Society
SERUM VASCULAR ENDOTHELIAL GROWTH FACTOR LEVEL IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES|
Fuat Erdem , Mehmet Gündogdu, Ahmet Kiziltunç
Angiogenesis is an important factor in tumoral progression, metastasis and invasion. More recently, it has also been found to play a particular role in hematological malignancies.
In this study, 45 patients harboring hematological malignancies (15 acute myeloid leukemia (AML), 10 acute lymphoblastic leukemia (ALL), 10 multiple myeloma (MM), 10 chronic myeloid leukemia (CML)) were compared with 20 healthy individuals matched according to age and sex, regarding serum vascular endothelial growth factor (VEGF, a marker for angiogenesis) levels.
The difference between serum VEGF levels of the study group (338.4 ± 587.6 pg/mL) and the control group (69.9 ± 24.4 pg/mL) was statistically significant (p<0.05). The highest serum VEGF level (1099.7±906.8 pg/mL) was found in CML subgroup.
Serum VEGF levels of the patients with hematological malignancies were significantly higher compared to controls. Further studies are needed to determine the exact role of VEGF in the development and progression of the hematological malignancies and therapeutic implications of this finding.
Serum Vascular Endothelial Growth Factor (VEGF), Hematological Malignancy
Alternative site location: http://www.ejgm.org